|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||15.87 - 15.94|
|52-week range||11.65 - 21.05|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.59 (3.73%)|
|Ex-dividend date||28 Apr 2021|
|1y target est||N/A|
Cancer victims are asking a federal judge overseeing thousands of Roundup weed killer cancer lawsuits to reject a proposed settlement that would allow the glyphosate-based herbicide to remain on store shelves while shielding Bayer AG (OTCMKTS: BAYRY) from future cancer lawsuits.
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Bayer Aktiengesellschaft (“Bayer” or the “Company”) (OTC: BAYRY, BAYZF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PlayAGS securities between May 23, 2016 and March 19, 2019, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/bayry.This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that material adverse facts. Specifically the complaint alleges that defendants willfully or recklessly made and/or caused the Company to make false and misleading statements that failed to disclose that the Monsanto acquisition would burden Bayer with significant exposure to the risk of suffering billions of dollars in judgments and reputational damage, among other things, if lawsuits brought against Monsanto alleging that exposure to its glyphosate-based Roundup product caused cancer, were successful. As a result, defendants’ positive statements about the prospects of the Monsanto acquisition and the benefits it would create for Bayer’s business were materially false and/or misleading and/or lacked a reasonable basis.A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/bayry or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Bayer you have until September 14, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | email@example.com
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Bayer Aktiengesellschaft.